Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sagopilone+ prednisone · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Sagopilone (ZK 219477) + prednisone | DRUG | Chemotherapy for hormone refractory prostate cancer; 16mg/m2 (up to 32mg/m2 max) IV on day 1 or each 21 day cycle for 6 cycles or until progression or unacceptable toxicity. |
Inclusion Criteria: * Must have evidence of confirmed metastatic prostate cancer * Serum testosterone must be less than 50 ng/mL * Disease must be progressing despite anti-androgen therapy * PSA level must be elevated * Additional criteria determined at screening visit Exclusion Criteria: * Any p...
Top 20 of 53 competitors
Sagopilone is an investigational small molecule being studied for the treatment of several cancers, including non-small cell lung cancer, small cell lung cancer, breast cancer, and prostate cancer. It has been evaluated in clinical trials for these oncology indications, though it remains in clinical development and is not approved.
Sagopilone is being developed by Bayer AG, a German pharmaceutical company. Bayer AG is publicly traded under the ticker symbol BAYRY on the OTC market. The company has sponsored clinical trials of Sagopilone in oncology indications.
Sagopilone has completed Phase 2 clinical trials for non-small cell lung cancer and breast cancer, and Phase 1 trials for small cell lung cancer and other neoplasms. It is an investigational drug, meaning it has not been approved by regulatory authorities and remains in clinical development.
Sagopilone has been studied in several completed clinical trials. NCT00160069 was a Phase 2 trial in non-small cell lung cancer with 128 participants in Germany. NCT00313248 was a Phase 2 trial in breast cancer with 65 participants in the US and Canada. NCT00359359 was a Phase 1 trial combining Sagopilone with cisplatin in small cell lung cancer, and NCT00432302 was a Phase 1 mass balance study.
Sagopilone is a distinct investigational agent developed by Bayer AG. No alternative names for Sagopilone have been reported. It is a small molecule chemotherapy agent being evaluated for its safety and efficacy in treating various solid tumors, including lung and breast cancers.